What is the clinical evidence from this study?

Study design: RCT. Population: Heart failure (n=550). Intervention: Pulmonary artery pressure-guided management vs. Usual care. Primary outcome: Rate of hospital admissions for heart failure (HR 0.67, 95% CI 0.55-0.80, p=<0.0001).

What does this research mean for the field?

Pulmonary artery pressure-guided management using an implanted sensor provides sustained long-term reductions in heart failure hospital admissions compared with usual care in NYHA Class III heart failure patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This trial investigates the long-term efficacy of managing chronic heart failure using pulmonary artery pressure data to lower hospital admission rates.

August 11, 2026The Lancet

Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial

Q: What are the key findings of this study?

Pulmonary artery pressure-guided management significantly reduced the rate of hospital admissions for heart failure compared with usual care (HR 0.67; 95% CI 0.55-0.80; p<0.0001).

Q: What does this research mean for the field?

Pulmonary artery pressure-guided management using an implanted sensor provides sustained long-term reductions in heart failure hospital admissions compared with usual care in NYHA Class III heart failure patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

This trial investigates the long-term efficacy of managing chronic heart failure using pulmonary artery pressure data to lower hospital admission rates.

View Full Paper

Ask AI

Bookmark

Key result

Pulmonary artery pressure-guided management reduces heart failure admissions ~33% versus usual care.

HR 0.67
95% CI 0.55-0.80
P<0.0001
n=550

Why the study?

Following initial 6-month reductions in heart failure hospital admissions with pulmonary artery pressure-guided management in the CHAMPION trial, extended efficacy over 18 months and subsequent open-access pressure information remained to be examined.

Does pulmonary artery pressure-guided management reduce hospital admissions in patients with NYHA Class III heart failure and a previous admission?

Key Points

This trial investigates the long-term efficacy of managing chronic heart failure using pulmonary artery pressure data to lower hospital admission rates.
Randomized clinical trial with 550 participants suffering from NYHA Class III heart failure.
Participants were assigned to receive either pulmonary artery pressure monitoring or usual care for an average of 18 months followed by a 13-month open access period.
Primary outcome measured was the rate of hospital admissions for heart failure in both treatment and control groups across randomized and open access periods.
During the randomized access period, hospital admission rates for the treatment group decreased by 33% (HR 0.67, 95% CI 0.55-0.80, p<0.0001) compared to controls.
After access to pulmonary artery pressure information, the former control group's admissions decreased by 48% (HR 0.52, 95% CI 0.40-0.69, p<0.0001) relative to the randomized access period.
Complications included 1% device-related and 1% procedure-related adverse events.

Study Design

Type

RCT (n=550)

Blinding

Single-blind

Randomization

1:1 by centre in block sizes of four

Multicenter

Yes

Structured PICO

Does pulmonary artery pressure-guided management reduce hospital admissions in patients with NYHA Class III heart failure and a previous admission?

Population

550 patients with NYHA Class III heart failure and a previous hospital admission, followed for an average of 18 months.

Intervention

Medical therapy guided by daily uploaded pulmonary artery pressures from an implanted pressure sensor.

Comparator

Usual care (daily uploaded pressures not made available to investigators; patients received all standard medical, device, and disease management strategies available).

Outcome

Rate of hospital admissions between the treatment group and control group in both the randomised access and open access periods.hard clinical

Main Result

Hazard Ratio: 0.67 (95% CI 0.55–0.8)

p-value: p=<0.0001

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Management of NYHA Class III heart failure based on home transmission of pulmonary artery pressure with an implanted pressure sensor has significant long-term benefit in lowering hospital admission rates for heart failure.

Cite This Study

Abraham et al. (2015) conducted an RCT in Heart failure (n=550). Pulmonary artery pressure-guided management vs. Usual care was evaluated on Rate of hospital admissions for heart failure (HR 0.67, 95% CI 0.55-0.80, p=<0.0001). Pulmonary artery pressure-guided management significantly reduced the rate of hospital admissions for heart failure compared with usual care (HR 0.67; 95% CI 0.55-0.80; p<0.0001).

synapsesocial.com/papers/6a7b71f34aa654994ddc2dbb https://doi.org/10.1016/s0140-6736(15)00723-0

Topics

HFrEF treatment Heart failure HFpEF management

View Full Paper

Ask AI

Bookmark

Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Topics

Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Keep reading

Topics

Keep reading